Citi analyst Mathieu Chevrie upgraded ResMed to Buy from Neutral with a A$37 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RMD:
- ResMed upgraded to Overweight from Neutral at JPMorgan
- ResMed to Report Second Quarter Fiscal 2023 Earnings on January 26, 2023
- ResMed Announces Participation in the 41st Annual J.P. Morgan Healthcare Conference
- ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions